From the Guidelines
The recommended dose of tralokinumab for adult patients with severe atopic dermatitis is an initial dose of 600 mg followed by 300 mg administered every 2 weeks. This dosing regimen is based on the most recent and highest quality study, which demonstrated significant improvements in the signs and symptoms of atopic dermatitis as well as quality of life 1. The treatment algorithm for adults with atopic dermatitis, as outlined in the guidelines of care, suggests considering additional treatment with phototherapy and/or systemic agents, such as tralokinumab, when topical therapy and basic management are optimized 1. Some key points to consider when administering tralokinumab include:
- Tralokinumab is a monoclonal antibody targeting interleukin-13, which plays a key role in the pathogenesis of atopic dermatitis 1
- The medication can be used with or without topical corticosteroids, and patients may self-administer after proper training
- Common side effects include upper respiratory tract infections, conjunctivitis, and injection site reactions, and patients should be monitored for allergic reactions and conjunctivitis during treatment
- There are no major safety concerns identified in clinical trials, but tralokinumab is somewhat less effective than dupilumab at 16 weeks of treatment, according to network meta-analysis 1
From the Research
Dose of Tralokinumab for Adult Severe Atopic Dermatitis
- The dose of tralokinumab for adult severe atopic dermatitis is 300 mg every 2 weeks, as indicated in studies 2, 3, 4.
- This dosing regimen has been shown to be effective in treating moderate-to-severe atopic dermatitis in adults, with an acceptable tolerability profile 2, 4.
- Tralokinumab has also been used in combination with topical corticosteroids, and has been found to be well-tolerated and effective in patients with severe atopic dermatitis who have an inadequate response to or intolerance of ciclosporin A 3.
- Real-life experience with tralokinumab has also shown it to be an effective first-line biotherapy for severe atopic dermatitis, with a favorable safety profile 5.
Key Findings
- Tralokinumab 300 mg every 2 weeks was superior to placebo in achieving a 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16 2, 3.
- Tralokinumab was well-tolerated, with the most common adverse events being flares of eczema and reactions at the injection site 5.
- Tralokinumab has been shown to be effective in combination with topical corticosteroids, and may be considered as an innovative option for the treatment of moderate-to-severe atopic dermatitis 3, 4.